170 related articles for article (PubMed ID: 29465264)
1. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Leuk Lymphoma; 2018 Nov; 59(11):2686-2691. PubMed ID: 29465264
[TBL] [Abstract][Full Text] [Related]
2. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
3. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
4. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
[TBL] [Abstract][Full Text] [Related]
5. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
6. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.
Rozovski U; Grgurevic S; Bueso-Ramos C; Harris DM; Li P; Liu Z; Wu JY; Jain P; Wierda W; Burger J; O'Brien S; Jain N; Ferrajoli A; Keating MJ; Estrov Z
Mol Cancer Res; 2015 May; 13(5):944-53. PubMed ID: 25733697
[TBL] [Abstract][Full Text] [Related]
7. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
8. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
9. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
Pallasch CP; Schwamb J; Königs S; Schulz A; Debey S; Kofler D; Schultze JL; Hallek M; Ultsch A; Wendtner CM
Leukemia; 2008 Mar; 22(3):585-92. PubMed ID: 18079738
[TBL] [Abstract][Full Text] [Related]
10. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E
Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317
[TBL] [Abstract][Full Text] [Related]
12. Metabolism pathways in chronic lymphocytic leukemia.
Rozovski U; Hazan-Halevy I; Barzilai M; Keating MJ; Estrov Z
Leuk Lymphoma; 2016; 57(4):758-65. PubMed ID: 26643954
[TBL] [Abstract][Full Text] [Related]
13. Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Chanas-Larue A; Villalpando-Rodriguez GE; Henson ES; Johnston JB; Gibson SB
Leuk Res; 2020 Sep; 96():106423. PubMed ID: 32712432
[TBL] [Abstract][Full Text] [Related]
14. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Wolf C; Garding A; Filarsky K; Bahlo J; Robrecht S; Becker N; Zucknick M; Rouhi A; Weigel A; Claus R; Weichenhan D; Eichhorst B; Fischer K; Hallek M; Kuchenbauer F; Plass C; Döhner H; Stilgenbauer S; Lichter P; Mertens D
Int J Cancer; 2018 Jan; 142(2):322-333. PubMed ID: 28921505
[TBL] [Abstract][Full Text] [Related]
15. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M
Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M
Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Shi Y; Wang G; Muhowski EM; McCaw L; Wang C; Bjarnason G; Woyach JA; Spaner DE
Leukemia; 2019 Jul; 33(7):1650-1662. PubMed ID: 30696950
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomics Reveals the Role of Constitutive KAP1 Phosphorylation by B-cell Receptor Signaling in Chronic Lymphocytic Leukemia.
Wu JL; Wu HY; Wu SJ; Tsai HY; Weng SH; Lin KT; Lin LI; Yao CY; Zamanova M; Lee YY; Angata T; Tien HF; Chen YJ; Lin KI
Mol Cancer Res; 2022 Aug; 20(8):1222-1232. PubMed ID: 35533307
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
[Next] [New Search]
